Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer

IFNγ is conventionally recognized as an inflammatory cytokine that plays a central role in antitumor immunity. Although it has been used clinically to treat a variety of malignancies, low levels of IFNγ in the tumor microenvironment (TME) increase the risk of tumor metastasis during immunotherapy. A...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 79; no. 14; pp. 3737 - 3748
Main Authors Song, Mengjia, Ping, Yu, Zhang, Kai, Yang, Li, Li, Feng, Zhang, Chaoqi, Cheng, Shaoyan, Yue, Dongli, Maimela, Nomathamsanqa Resegofetse, Qu, Jiao, Liu, Shasha, Sun, Ting, Li, Zihai, Xia, Jianchuan, Zhang, Bin, Wang, Liping, Zhang, Yi
Format Journal Article
LanguageEnglish
Published United States 15.07.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract IFNγ is conventionally recognized as an inflammatory cytokine that plays a central role in antitumor immunity. Although it has been used clinically to treat a variety of malignancies, low levels of IFNγ in the tumor microenvironment (TME) increase the risk of tumor metastasis during immunotherapy. Accumulating evidence suggests that IFNγ can induce cancer progression, yet the mechanisms underlying the controversial role of IFNγ in tumor development remain unclear. Here, we reveal a dose-dependent effect of IFNγ in inducing tumor stemness to accelerate cancer progression in patients with a variety of cancer types. Low levels of IFNγ endowed cancer stem-like properties via the intercellular adhesion molecule-1 (ICAM1)-PI3K-Akt-Notch1 axis, whereas high levels of IFNγ activated the JAK1-STAT1-caspase pathway to induce apoptosis in non-small cell lung cancer (NSCLC). Inhibition of ICAM1 abrogated the stem-like properties of NSCLC cells induced by the low dose of IFNγ both and . This study unveils the role of low levels of IFNγ in conferring tumor stemness and elucidates the distinct signaling pathways activated by IFNγ in a dose-dependent manner, thus providing new insights into cancer treatment, particularly for patients with low expression of IFNγ in the TME. SIGNIFICANCE: These findings reveal the dose-dependent effect of IFNγ in inducing tumor stemness and elucidate the distinct molecular mechanisms activated by IFNγ in a dose-dependent manner.
AbstractList Abstract IFNγ is conventionally recognized as an inflammatory cytokine that plays a central role in antitumor immunity. Although it has been used clinically to treat a variety of malignancies, low levels of IFNγ in the tumor microenvironment (TME) increase the risk of tumor metastasis during immunotherapy. Accumulating evidence suggests that IFNγ can induce cancer progression, yet the mechanisms underlying the controversial role of IFNγ in tumor development remain unclear. Here, we reveal a dose-dependent effect of IFNγ in inducing tumor stemness to accelerate cancer progression in patients with a variety of cancer types. Low levels of IFNγ endowed cancer stem-like properties via the intercellular adhesion molecule-1 (ICAM1)–PI3K–Akt–Notch1 axis, whereas high levels of IFNγ activated the JAK1–STAT1–caspase pathway to induce apoptosis in non–small cell lung cancer (NSCLC). Inhibition of ICAM1 abrogated the stem-like properties of NSCLC cells induced by the low dose of IFNγ both in vitro and in vivo. This study unveils the role of low levels of IFNγ in conferring tumor stemness and elucidates the distinct signaling pathways activated by IFNγ in a dose-dependent manner, thus providing new insights into cancer treatment, particularly for patients with low expression of IFNγ in the TME. Significance: These findings reveal the dose-dependent effect of IFNγ in inducing tumor stemness and elucidate the distinct molecular mechanisms activated by IFNγ in a dose-dependent manner.
IFNγ is conventionally recognized as an inflammatory cytokine that plays a central role in antitumor immunity. Although it has been used clinically to treat a variety of malignancies, low levels of IFNγ in the tumor microenvironment (TME) increase the risk of tumor metastasis during immunotherapy. Accumulating evidence suggests that IFNγ can induce cancer progression, yet the mechanisms underlying the controversial role of IFNγ in tumor development remain unclear. Here, we reveal a dose-dependent effect of IFNγ in inducing tumor stemness to accelerate cancer progression in patients with a variety of cancer types. Low levels of IFNγ endowed cancer stem-like properties via the intercellular adhesion molecule-1 (ICAM1)-PI3K-Akt-Notch1 axis, whereas high levels of IFNγ activated the JAK1-STAT1-caspase pathway to induce apoptosis in non-small cell lung cancer (NSCLC). Inhibition of ICAM1 abrogated the stem-like properties of NSCLC cells induced by the low dose of IFNγ both and . This study unveils the role of low levels of IFNγ in conferring tumor stemness and elucidates the distinct signaling pathways activated by IFNγ in a dose-dependent manner, thus providing new insights into cancer treatment, particularly for patients with low expression of IFNγ in the TME. SIGNIFICANCE: These findings reveal the dose-dependent effect of IFNγ in inducing tumor stemness and elucidate the distinct molecular mechanisms activated by IFNγ in a dose-dependent manner.
Author Ping, Yu
Liu, Shasha
Wang, Liping
Yang, Li
Li, Feng
Sun, Ting
Cheng, Shaoyan
Zhang, Yi
Xia, Jianchuan
Zhang, Kai
Li, Zihai
Qu, Jiao
Yue, Dongli
Zhang, Chaoqi
Zhang, Bin
Song, Mengjia
Maimela, Nomathamsanqa Resegofetse
Author_xml – sequence: 1
  givenname: Mengjia
  surname: Song
  fullname: Song, Mengjia
  organization: Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China
– sequence: 2
  givenname: Yu
  surname: Ping
  fullname: Ping, Yu
  organization: Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
– sequence: 3
  givenname: Kai
  surname: Zhang
  fullname: Zhang, Kai
  organization: Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
– sequence: 4
  givenname: Li
  surname: Yang
  fullname: Yang, Li
  organization: Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
– sequence: 5
  givenname: Feng
  surname: Li
  fullname: Li, Feng
  organization: Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
– sequence: 6
  givenname: Chaoqi
  surname: Zhang
  fullname: Zhang, Chaoqi
  organization: Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
– sequence: 7
  givenname: Shaoyan
  surname: Cheng
  fullname: Cheng, Shaoyan
  organization: Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
– sequence: 8
  givenname: Dongli
  surname: Yue
  fullname: Yue, Dongli
  organization: Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
– sequence: 9
  givenname: Nomathamsanqa Resegofetse
  surname: Maimela
  fullname: Maimela, Nomathamsanqa Resegofetse
  organization: Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
– sequence: 10
  givenname: Jiao
  surname: Qu
  fullname: Qu, Jiao
  organization: Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
– sequence: 11
  givenname: Shasha
  surname: Liu
  fullname: Liu, Shasha
  organization: Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
– sequence: 12
  givenname: Ting
  surname: Sun
  fullname: Sun, Ting
  organization: Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
– sequence: 13
  givenname: Zihai
  surname: Li
  fullname: Li, Zihai
  organization: Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina
– sequence: 14
  givenname: Jianchuan
  surname: Xia
  fullname: Xia, Jianchuan
  organization: Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China
– sequence: 15
  givenname: Bin
  surname: Zhang
  fullname: Zhang, Bin
  organization: Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois
– sequence: 16
  givenname: Liping
  surname: Wang
  fullname: Wang, Liping
  email: yizhang@zzu.edu.cn, wlp@zzu.edu.cn
  organization: Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. yizhang@zzu.edu.cn wlp@zzu.edu.cn
– sequence: 17
  givenname: Yi
  surname: Zhang
  fullname: Zhang, Yi
  email: yizhang@zzu.edu.cn, wlp@zzu.edu.cn
  organization: Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31085700$$D View this record in MEDLINE/PubMed
BookMark eNo9kEtOwzAURS0Eoh9YAshDJi7PThw7wypQqBTKoGVsOYmDghq7xAmIdbEP1kRCS0fWs859nzNBp9ZZg9AVhRmlXN4CgCQ8FGyWzFeExgR4HJ2gMeWBJCIM-SkaH5kRmnj_1pecAj9Ho4CC5AJgjLLUfZI75w1eLlY_33hpiy43Hm-62jU4MdstXremtsZ7XNnD91OVN87Yj6pxtja2xa7EK2fJutY9_xdKO_uKE21z01ygs1Jvvbk8vFP0srjfJI8kfX5YJvOU5EEMLZGaxpzneQyBZFEJEoBFIApRBDLWBZMyMyGVPIQozJgQLI80LcMoCxktpKTBFN3s--4a994Z36q68nm_jLbGdV4xFjCgkWBxj_I92t_hfWNKtWuqWjdfioIa9KpBnRrUqV6vorEa9Pa568OILqtNcUz9-wx-AaAkdgM
CitedBy_id crossref_primary_10_1038_s41590_022_01198_y
crossref_primary_10_3389_fonc_2021_732081
crossref_primary_10_3390_pharmaceutics15072001
crossref_primary_10_1016_j_freeradbiomed_2023_12_034
crossref_primary_10_3389_fimmu_2020_00526
crossref_primary_10_3389_fcell_2020_00803
crossref_primary_10_1016_j_canlet_2024_216647
crossref_primary_10_3389_fimmu_2022_1057181
crossref_primary_10_3389_fimmu_2022_1042368
crossref_primary_10_3389_fphar_2023_1130937
crossref_primary_10_1089_jir_2022_0132
crossref_primary_10_3389_fgene_2022_979575
crossref_primary_10_3892_ol_2024_14392
crossref_primary_10_1002_ctm2_525
crossref_primary_10_3390_jpm12040556
crossref_primary_10_1134_S1990519X23060111
crossref_primary_10_1158_2643_3230_BCD_21_0181
crossref_primary_10_3389_fonc_2022_885656
crossref_primary_10_5306_wjco_v15_i2_195
crossref_primary_10_1038_s41388_024_03042_z
crossref_primary_10_18632_oncotarget_27977
crossref_primary_10_3390_ijms232012327
crossref_primary_10_3389_fcell_2022_908389
crossref_primary_10_3389_fendo_2022_929572
crossref_primary_10_3390_cells10102515
crossref_primary_10_1002_adhm_202304144
crossref_primary_10_1007_s12013_023_01182_9
crossref_primary_10_1002_JLB_3MA1220_815RRR
crossref_primary_10_1007_s00262_021_02872_0
crossref_primary_10_18699_SSMJ20230202
crossref_primary_10_3389_fimmu_2022_959114
crossref_primary_10_1042_EBC20230001
crossref_primary_10_1172_jci_insight_157285
crossref_primary_10_1186_s12964_023_01267_1
crossref_primary_10_1038_s41416_020_1022_4
crossref_primary_10_1080_14760584_2021_1927724
crossref_primary_10_1016_j_phrs_2024_107221
crossref_primary_10_1038_s41467_023_35948_9
crossref_primary_10_1002_cam4_6605
crossref_primary_10_3389_fnut_2023_1270920
crossref_primary_10_1158_1078_0432_CCR_20_1420
crossref_primary_10_1038_s42003_024_06402_3
crossref_primary_10_1002_cac2_12449
crossref_primary_10_1038_s41416_024_02601_1
crossref_primary_10_1016_j_reth_2021_02_006
crossref_primary_10_1093_carcin_bgab097
crossref_primary_10_3389_fimmu_2023_1269015
crossref_primary_10_3390_biomedicines11010008
crossref_primary_10_3390_cancers14020263
crossref_primary_10_3390_cancers13030533
crossref_primary_10_1007_s00432_021_03601_x
crossref_primary_10_1038_s41419_023_05609_2
crossref_primary_10_3389_fimmu_2023_1190333
crossref_primary_10_1038_s41586_022_04585_5
crossref_primary_10_1038_s41598_023_43937_7
crossref_primary_10_1016_j_esmoop_2021_100253
crossref_primary_10_1016_j_biomaterials_2022_121936
crossref_primary_10_3390_ph17030299
crossref_primary_10_1016_j_phrs_2020_105094
crossref_primary_10_1016_j_cyto_2021_155442
crossref_primary_10_1016_j_bbcan_2020_188439
crossref_primary_10_1038_s12276_023_01014_z
crossref_primary_10_12688_f1000research_130316_1
crossref_primary_10_3389_fgene_2022_823075
crossref_primary_10_1002_advs_202204565
crossref_primary_10_3390_ijms242417325
crossref_primary_10_1016_j_celrep_2020_108597
crossref_primary_10_3390_ijms24044002
crossref_primary_10_1016_j_eujim_2020_101241
crossref_primary_10_15252_embr_202052252
crossref_primary_10_3389_fgene_2022_890174
crossref_primary_10_3390_cells10092361
crossref_primary_10_1186_s12890_023_02809_6
crossref_primary_10_1063_5_0156628
crossref_primary_10_3389_fimmu_2020_00140
crossref_primary_10_1002_ptr_7307
crossref_primary_10_1016_j_cbi_2021_109370
crossref_primary_10_1016_j_stem_2023_05_007
crossref_primary_10_3389_fonc_2022_864021
crossref_primary_10_1158_0008_5472_CAN_22_0571
crossref_primary_10_3390_pharmaceutics15020377
crossref_primary_10_1186_s12943_022_01682_x
Cites_doi 10.1182/blood.V78.4.1085.1085
10.1124/mol.58.6.1479
10.1038/labinvest.2011.91
10.1158/1078-0432.CCR-06-1393
10.1002/ijc.23553
10.1002/ijc.2910300217
10.1038/nature19364
10.1172/JCI80445
10.1172/JCI91190
10.4049/jimmunol.141.5.1665
10.1038/ncomms14035
10.3389/fonc.2017.00080
10.1074/jbc.272.1.435
10.1172/JCI88959
10.1371/journal.pone.0142834
10.1093/emboj/18.8.2196
10.1111/j.1600-065X.2008.00610.x
10.1126/scitranslmed.aad7118
10.1038/nm.4409
10.1038/bjc.1985.143
10.1016/j.cell.2008.03.027
10.1016/S1734-1140(09)70004-0
10.1016/j.celrep.2017.07.075
10.1038/nri1604
10.1074/jbc.M116.748970
10.1016/j.stem.2015.02.015
10.1371/journal.pone.0003077
10.1006/scbi.2000.0314
10.1158/1078-0432.CCR-17-2008
10.1126/scitranslmed.3006504
10.1158/0008-5472.CAN-08-3479
10.1097/00002371-199907000-00005
10.1038/s41591-018-0302-5
10.1074/jbc.M804888200
10.1007/s00262-004-0654-1
10.1038/nrclinonc.2015.61
10.1016/j.ccr.2008.04.001
10.1172/JCI87324
10.1038/ncb1356
10.1038/onc.2017.387
10.1038/ncomms15207
10.1053/j.gastro.2013.01.046
10.1007/s13238-016-0367-1
ContentType Journal Article
Copyright 2019 American Association for Cancer Research.
Copyright_xml – notice: 2019 American Association for Cancer Research.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1158/0008-5472.CAN-19-0596
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1538-7445
EndPage 3748
ExternalDocumentID 10_1158_0008_5472_CAN_19_0596
31085700
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-ET
18M
29B
2WC
34G
39C
476
53G
5GY
5RE
5VS
6J9
ABOCM
ACGFO
ACIWK
ACPRK
ACSVP
ADBBV
ADCOW
ADNWM
AENEX
AFHIN
AFOSN
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CGR
CS3
CUY
CVF
DIK
DU5
EBS
ECM
EIF
EJD
F5P
FRP
GX1
H13
IH2
KQ8
L7B
LSO
NPM
OK1
P0W
P2P
PQQKQ
RCR
RHF
RHI
RNS
SJN
TR2
W2D
W8F
WH7
WOQ
YKV
YZZ
AAYXX
CITATION
7X8
AETEA
ID FETCH-LOGICAL-c390t-8a1955cc903826f08002607d7d389ad288be41854064b2772c6a1f46b421d8813
ISSN 0008-5472
IngestDate Sat Aug 17 03:25:08 EDT 2024
Thu Sep 26 18:07:43 EDT 2024
Sat Sep 28 08:29:28 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 14
Language English
License 2019 American Association for Cancer Research.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c390t-8a1955cc903826f08002607d7d389ad288be41854064b2772c6a1f46b421d8813
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://cancerres.aacrjournals.org/content/canres/79/14/3737.full.pdf
PMID 31085700
PQID 2232016729
PQPubID 23479
PageCount 12
ParticipantIDs proquest_miscellaneous_2232016729
crossref_primary_10_1158_0008_5472_CAN_19_0596
pubmed_primary_31085700
PublicationCentury 2000
PublicationDate 2019-07-15
20190715
PublicationDateYYYYMMDD 2019-07-15
PublicationDate_xml – month: 07
  year: 2019
  text: 2019-07-15
  day: 15
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Cancer research (Chicago, Ill.)
PublicationTitleAlternate Cancer Res
PublicationYear 2019
References Ohtsuka (2022061706295658700_bib33) 1999; 18
Murohashi (2022061706295658700_bib5) 1991; 78
Huang (2022061706295658700_bib42) 2016; 126
Mani (2022061706295658700_bib15) 2008; 133
Plaks (2022061706295658700_bib16) 2015; 16
Lin (2022061706295658700_bib29) 2006; 12
Tsai (2022061706295658700_bib25) 2015; 10
Ping (2022061706295658700_bib43) 2018; 9
Twentyman (2022061706295658700_bib38) 1985; 52
Sadanaga (2022061706295658700_bib2) 1999; 22
Qiao (2022061706295658700_bib17) 2017; 37
Rothlein (2022061706295658700_bib22) 1988; 141
Zou (2022061706295658700_bib44) 2016; 8
Ayers (2022061706295658700_bib7) 2017; 127
Liu (2022061706295658700_bib11) 2017; 8
Duperray (2022061706295658700_bib19) 1997; 272
Huang (2022061706295658700_bib26) 2017; 8
Gato-Canas (2022061706295658700_bib37) 2017; 20
Gong (2022061706295658700_bib10) 2008; 123
Liu (2022061706295658700_bib24) 2013; 144
Balkwill (2022061706295658700_bib39) 1982; 30
Chen (2022061706295658700_bib23) 2000; 58
Lawson (2022061706295658700_bib18) 2009; 61
Kanters (2022061706295658700_bib21) 2008; 283
Liu (2022061706295658700_bib40) 2019; 25
Roy (2022061706295658700_bib31) 2017; 292
Eil (2022061706295658700_bib30) 2016; 537
Zakaria (2022061706295658700_bib32) 2017; 7
Takebe (2022061706295658700_bib14) 2015; 12
Levina (2022061706295658700_bib28) 2008; 3
Millan (2022061706295658700_bib20) 2006; 8
Chauvin (2022061706295658700_bib34) 2015; 125
Spranger (2022061706295658700_bib36) 2013; 5
Muller-Hermelink (2022061706295658700_bib4) 2008; 13
He (2022061706295658700_bib8) 2005; 54
Kelly (2022061706295658700_bib9) 1991; 51
Katz (2022061706295658700_bib35) 2008; 222
Tannenbaum (2022061706295658700_bib1) 2000; 10
Platanias (2022061706295658700_bib3) 2005; 5
Batlle (2022061706295658700_bib13) 2017; 23
Daud (2022061706295658700_bib41) 2016; 126
Min (2022061706295658700_bib27) 2017; 23
Xiao (2022061706295658700_bib6) 2009; 69
Chen (2022061706295658700_bib12) 2011; 91
References_xml – volume: 78
  start-page: 1085
  year: 1991
  ident: 2022061706295658700_bib5
  article-title: Interferon-gamma enhances growth factor-dependent proliferation of clonogenic cells in acute myeloblastic leukemia
  publication-title: Blood
  doi: 10.1182/blood.V78.4.1085.1085
  contributor:
    fullname: Murohashi
– volume: 58
  start-page: 1479
  year: 2000
  ident: 2022061706295658700_bib23
  article-title: Protein kinase calpha but not p44/42 mitogen-activated protein kinase, p38, or c-Jun NH(2)-terminal kinase is required for intercellular adhesion molecule-1 expression mediated by interleukin-1beta: involvement of sequential activation of tyrosine kinase, nuclear factor-kappaB-inducing kinase, and IkappaB kinase 2
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.58.6.1479
  contributor:
    fullname: Chen
– volume: 91
  start-page: 1502
  year: 2011
  ident: 2022061706295658700_bib12
  article-title: Induction of metastatic cancer stem cells from the NK/LAK-resistant floating, but not adherent, subset of the UP-LN1 carcinoma cell line by IFN-gamma
  publication-title: Lab Invest
  doi: 10.1038/labinvest.2011.91
  contributor:
    fullname: Chen
– volume: 12
  start-page: 7165
  year: 2006
  ident: 2022061706295658700_bib29
  article-title: A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-1393
  contributor:
    fullname: Lin
– volume: 123
  start-page: 702
  year: 2008
  ident: 2022061706295658700_bib10
  article-title: IFN-gamma withdrawal after immunotherapy potentiates B16 melanoma invasion and metastasis by intensifying tumor integrin alphavbeta3 signaling
  publication-title: Int J Cancer
  doi: 10.1002/ijc.23553
  contributor:
    fullname: Gong
– volume: 30
  start-page: 231
  year: 1982
  ident: 2022061706295658700_bib39
  article-title: Human interferon inhibits the growth of established human breast tumours in the nude mouse
  publication-title: Int J Cancer
  doi: 10.1002/ijc.2910300217
  contributor:
    fullname: Balkwill
– volume: 537
  start-page: 539
  year: 2016
  ident: 2022061706295658700_bib30
  article-title: Ionic immune suppression within the tumour microenvironment limits T cell effector function
  publication-title: Nature
  doi: 10.1038/nature19364
  contributor:
    fullname: Eil
– volume: 125
  start-page: 2046
  year: 2015
  ident: 2022061706295658700_bib34
  article-title: TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients
  publication-title: J Clin Invest
  doi: 10.1172/JCI80445
  contributor:
    fullname: Chauvin
– volume: 127
  start-page: 2930
  year: 2017
  ident: 2022061706295658700_bib7
  article-title: IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade
  publication-title: J Clin Invest
  doi: 10.1172/JCI91190
  contributor:
    fullname: Ayers
– volume: 141
  start-page: 1665
  year: 1988
  ident: 2022061706295658700_bib22
  article-title: Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies
  publication-title: J Immunol
  doi: 10.4049/jimmunol.141.5.1665
  contributor:
    fullname: Rothlein
– volume: 8
  start-page: 14035
  year: 2017
  ident: 2022061706295658700_bib26
  article-title: Tumour-derived interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression
  publication-title: Nat Commun
  doi: 10.1038/ncomms14035
  contributor:
    fullname: Huang
– volume: 7
  start-page: 80
  year: 2017
  ident: 2022061706295658700_bib32
  article-title: Targeting lung cancer stem cells: research and clinical impacts
  publication-title: Front Oncol
  doi: 10.3389/fonc.2017.00080
  contributor:
    fullname: Zakaria
– volume: 272
  start-page: 435
  year: 1997
  ident: 2022061706295658700_bib19
  article-title: Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging
  publication-title: J Biol Chem
  doi: 10.1074/jbc.272.1.435
  contributor:
    fullname: Duperray
– volume: 126
  start-page: 2795
  year: 2016
  ident: 2022061706295658700_bib42
  article-title: Driving an improved CAR for cancer immunotherapy
  publication-title: J Clin Invest
  doi: 10.1172/JCI88959
  contributor:
    fullname: Huang
– volume: 10
  start-page: e0142834
  year: 2015
  ident: 2022061706295658700_bib25
  article-title: ICAM1 is a potential cancer stem cell marker of esophageal squamous cell carcinoma
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0142834
  contributor:
    fullname: Tsai
– volume: 18
  start-page: 2196
  year: 1999
  ident: 2022061706295658700_bib33
  article-title: Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation
  publication-title: EMBO J
  doi: 10.1093/emboj/18.8.2196
  contributor:
    fullname: Ohtsuka
– volume: 222
  start-page: 206
  year: 2008
  ident: 2022061706295658700_bib35
  article-title: Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape
  publication-title: Immunol Rev
  doi: 10.1111/j.1600-065X.2008.00610.x
  contributor:
    fullname: Katz
– volume: 8
  start-page: 328rv4
  year: 2016
  ident: 2022061706295658700_bib44
  article-title: PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.aad7118
  contributor:
    fullname: Zou
– volume: 23
  start-page: 1124
  year: 2017
  ident: 2022061706295658700_bib13
  article-title: Cancer stem cells revisited
  publication-title: Nat Med
  doi: 10.1038/nm.4409
  contributor:
    fullname: Batlle
– volume: 52
  start-page: 21
  year: 1985
  ident: 2022061706295658700_bib38
  article-title: The effects of alpha and gamma interferons on human lung cancer cells grown in vitro or as xenografts in nude mice
  publication-title: Br J Cancer
  doi: 10.1038/bjc.1985.143
  contributor:
    fullname: Twentyman
– volume: 133
  start-page: 704
  year: 2008
  ident: 2022061706295658700_bib15
  article-title: The epithelial-mesenchymal transition generates cells with properties of stem cells
  publication-title: Cell
  doi: 10.1016/j.cell.2008.03.027
  contributor:
    fullname: Mani
– volume: 61
  start-page: 22
  year: 2009
  ident: 2022061706295658700_bib18
  article-title: ICAM-1 signaling in endothelial cells
  publication-title: Pharmacol Rep
  doi: 10.1016/S1734-1140(09)70004-0
  contributor:
    fullname: Lawson
– volume: 20
  start-page: 1818
  year: 2017
  ident: 2022061706295658700_bib37
  article-title: PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2017.07.075
  contributor:
    fullname: Gato-Canas
– volume: 5
  start-page: 375
  year: 2005
  ident: 2022061706295658700_bib3
  article-title: Mechanisms of type-I- and type-II-interferon-mediated signalling
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri1604
  contributor:
    fullname: Platanias
– volume: 292
  start-page: 435
  year: 2017
  ident: 2022061706295658700_bib31
  article-title: Activation of D2 dopamine receptors in CD133+ve cancer stem cells in non-small cell lung carcinoma inhibits proliferation, clonogenic ability, and invasiveness of these cells
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M116.748970
  contributor:
    fullname: Roy
– volume: 16
  start-page: 225
  year: 2015
  ident: 2022061706295658700_bib16
  article-title: The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2015.02.015
  contributor:
    fullname: Plaks
– volume: 3
  start-page: e3077
  year: 2008
  ident: 2022061706295658700_bib28
  article-title: Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0003077
  contributor:
    fullname: Levina
– volume: 51
  start-page: 4020
  year: 1991
  ident: 2022061706295658700_bib9
  article-title: Enhancement of metastatic potential by gamma-interferon
  publication-title: Cancer Res
  contributor:
    fullname: Kelly
– volume: 10
  start-page: 113
  year: 2000
  ident: 2022061706295658700_bib1
  article-title: Immune-inflammatory mechanisms in IFNgamma-mediated anti-tumor activity
  publication-title: Semin Cancer Biol
  doi: 10.1006/scbi.2000.0314
  contributor:
    fullname: Tannenbaum
– volume: 23
  start-page: 7569
  year: 2017
  ident: 2022061706295658700_bib27
  article-title: CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-2008
  contributor:
    fullname: Min
– volume: 5
  start-page: 200ra116
  year: 2013
  ident: 2022061706295658700_bib36
  article-title: Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3006504
  contributor:
    fullname: Spranger
– volume: 69
  start-page: 2010
  year: 2009
  ident: 2022061706295658700_bib6
  article-title: IFNgamma promotes papilloma development by up-regulating Th17-associated inflammation
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-3479
  contributor:
    fullname: Xiao
– volume: 22
  start-page: 315
  year: 1999
  ident: 2022061706295658700_bib2
  article-title: Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells
  publication-title: J Immunother
  doi: 10.1097/00002371-199907000-00005
  contributor:
    fullname: Sadanaga
– volume: 25
  start-page: 95
  year: 2019
  ident: 2022061706295658700_bib40
  article-title: Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0302-5
  contributor:
    fullname: Liu
– volume: 283
  start-page: 31830
  year: 2008
  ident: 2022061706295658700_bib21
  article-title: Filamin B mediates ICAM-1-driven leukocyte transendothelial migration
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M804888200
  contributor:
    fullname: Kanters
– volume: 54
  start-page: 891
  year: 2005
  ident: 2022061706295658700_bib8
  article-title: Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-004-0654-1
  contributor:
    fullname: He
– volume: 12
  start-page: 445
  year: 2015
  ident: 2022061706295658700_bib14
  article-title: Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2015.61
  contributor:
    fullname: Takebe
– volume: 13
  start-page: 507
  year: 2008
  ident: 2022061706295658700_bib4
  article-title: TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2008.04.001
  contributor:
    fullname: Muller-Hermelink
– volume: 126
  start-page: 3447
  year: 2016
  ident: 2022061706295658700_bib41
  article-title: Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma
  publication-title: J Clin Invest
  doi: 10.1172/JCI87324
  contributor:
    fullname: Daud
– volume: 8
  start-page: 113
  year: 2006
  ident: 2022061706295658700_bib20
  article-title: Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb1356
  contributor:
    fullname: Millan
– volume: 37
  start-page: 873
  year: 2017
  ident: 2022061706295658700_bib17
  article-title: IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma
  publication-title: Oncogene
  doi: 10.1038/onc.2017.387
  contributor:
    fullname: Qiao
– volume: 8
  start-page: 15207
  year: 2017
  ident: 2022061706295658700_bib11
  article-title: Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-gamma-induced immunologic dormancy of tumor-repopulating cells
  publication-title: Nat Commun
  doi: 10.1038/ncomms15207
  contributor:
    fullname: Liu
– volume: 144
  start-page: 1031
  year: 2013
  ident: 2022061706295658700_bib24
  article-title: Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2013.01.046
  contributor:
    fullname: Liu
– volume: 9
  start-page: 254
  year: 2018
  ident: 2022061706295658700_bib43
  article-title: T-cell receptor-engineered T cells for cancer treatment: current status and future directions
  publication-title: Protein Cell
  doi: 10.1007/s13238-016-0367-1
  contributor:
    fullname: Ping
SSID ssj0005105
Score 2.6142936
Snippet IFNγ is conventionally recognized as an inflammatory cytokine that plays a central role in antitumor immunity. Although it has been used clinically to treat a...
Abstract IFNγ is conventionally recognized as an inflammatory cytokine that plays a central role in antitumor immunity. Although it has been used clinically to...
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
StartPage 3737
SubjectTerms A549 Cells
Animals
Apoptosis - drug effects
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - metabolism
Carcinoma, Non-Small-Cell Lung - pathology
Caspases - metabolism
Cell Line, Tumor
Dose-Response Relationship, Drug
Female
Humans
Intercellular Adhesion Molecule-1 - metabolism
Interferon-gamma - administration & dosage
Janus Kinase 1 - metabolism
Lung Neoplasms - drug therapy
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Mice
Mice, Inbred NOD
Mice, SCID
Neoplastic Stem Cells - drug effects
Neoplastic Stem Cells - metabolism
Neoplastic Stem Cells - pathology
Phosphatidylinositol 3-Kinases - metabolism
Proto-Oncogene Proteins c-akt - metabolism
Receptor, Notch1 - metabolism
Recombinant Proteins - pharmacology
Signal Transduction - drug effects
STAT1 Transcription Factor - metabolism
Tumor Microenvironment - drug effects
Xenograft Model Antitumor Assays
Title Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/31085700
https://search.proquest.com/docview/2232016729
Volume 79
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3battAEF3cFEJeSu91b2yheTKrWlpdVo-pk5A0tinEgfRJ6LKiKrFkXItCf6v_0W_qzF5ktUmg7YswK2kXZo5HM7tnZgh5WxQZfLjLkuUZD7CFGWcxlxxinhT9dex2i8nJs3l4cuF_uAwuB4NVj7XUbjIn_35jXsn_aBXGQK-YJfsPmu0mhQH4DfqFK2gYrn-l42nzjR0i4fz0eL4_Odp_z0fYigNJVot22axHE6kOnuVSGbSqNsMzZOH1UtzUtkFTs_MlHlSrl6Yt8gEQEuu-_6pHRqZE0Gd1BqzJHMrYXF05va2Fc0P3Rebsl6qz_x9NG5VP7bVd67O06syQGZpW_Y0JlQvFdGqmI7fGNPJ1uUhrbXXrGIsqv2c7eaTLv1w36oHQLEjBADueMzmYM1wu0L1we4peLZWmuavr9m-_cR3z0N66Q-56URwgCfTw9GxLCgJ30-R5warvblxzj-zaWX53Zm6JUJSnsrhP7pkQgx5ovDwgA1k_JLszQ6J4RDILGwqw-fmDGshQhQ2K2qcWMrSqzfCfkKFNSTvI6JcQMlQD5DG5OD5aTE6YabXBch6PN0yk8L8M8jwec4g3SxVGhOOoiApwaNPCEyKTWOYI3D8_8yAiy8PULf0w8z23EMLlT8hO3dTyGaF-LHlccHwg8nOwBSVMKnmQg6kP3DAcEsfKLFnpiiqJikQDgUwIkaC8E5B34sYJyntI3ljJJmD78EArrWXTfk3AtfUwjcaLh-SpFnk3pVXR81vvvCB7W9i-JDubdStfgYe5yV4rUPwCT4txRQ
link.rule.ids 315,786,790,27955,27956
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low-Dose+IFN%CE%B3+Induces+Tumor+Cell+Stemness+in+Tumor+Microenvironment+of+Non-Small+Cell+Lung+Cancer&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Song%2C+Mengjia&rft.au=Ping%2C+Yu&rft.au=Zhang%2C+Kai&rft.au=Yang%2C+Li&rft.date=2019-07-15&rft.eissn=1538-7445&rft.volume=79&rft.issue=14&rft.spage=3737&rft_id=info:doi/10.1158%2F0008-5472.CAN-19-0596&rft_id=info%3Apmid%2F31085700&rft.externalDocID=31085700
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon